Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339813 | 0.87 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL27367676 | 0.87 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL10609652 | 0.82 | LMNA (0.75) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Benzylphenylether SCHEMBL61660 | 0.82 | LMNA (0.74) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL12260995 | 0.81 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9808056 | 0.80 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5538712 | 0.80 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL197017 | 0.80 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Benzylphenylether SCHEMBL23235842 | 0.80 | LMNA (0.71) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Benzylphenylether SCHEMBL9549322 | 0.80 | LMNA (0.71) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104803846-B | The method for preparing bis- [4- (6- acryloyl-oxy hexyl) phenyl] hexamethylene -1,4- dicarboxylic esters | 默克专利股份有限公司 | 2019-06-11 | — | — | CN | claimed |
| CN-104803846-A | Method for the preparation of bis[4-(6-acryloyloxy-hexyl)-phenyl]cyclohexane-1,4-dicarboxylate | MERCK PATENT GMBH | 2015-07-29 | — | — | CN | claimed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-03-04 | — | — | US | disclosed |
| CN-112153968-A | Process for the preparation of alpha-carboxamide pyrrolidine derivatives | 生物基因公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-107207473-B | Compounds having muscarinic receptor antagonist and β 2 adrenergic receptor agonist activity | 奇斯药制品公司 | 2020-07-07 | — | — | CN | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| CN-110066302-A | Glucopyranosyl derivatives and application thereof | 广东东阳光药业有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-104803846-B | The method for preparing bis- [4- (6- acryloyl-oxy hexyl) phenyl] hexamethylene -1,4- dicarboxylic esters | 默克专利股份有限公司 | 2019-06-11 | — | — | CN | disclosed |
| CN-108698973-A | Polymerizable compound and use its liquid-crystal composition | DIC株式会社 | 2018-10-23 | — | — | CN | disclosed |
| CN-106661008-A | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases | 拜耳制药股份公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106458938-A | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof | 拜耳制药股份公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-104803846-A | Method for the preparation of bis[4-(6-acryloyloxy-hexyl)-phenyl]cyclohexane-1,4-dicarboxylate | MERCK PATENT GMBH | 2015-07-29 | — | — | CN | disclosed |
| CN-102869667-A | Tricyclic pyridine derivatives, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INT | 2013-01-09 | — | — | CN | disclosed |
| CN-102656145-A | Modulators of G-protein coupled receptor 88 | BRISTOL MYERS SQUIBB CO | 2012-09-05 | — | — | CN | disclosed |
| CN-1950328-A | Phenyl indan derivatives | LUNDBECK & CO AS H (DK) | 2007-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | LMNA 3256/4885CYP1A2 4354/4885PTGS1 1593/4885 |
| US-20210061839-A1 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | SLC5A1, SLC5A2, UGGT1 | LMNA 4427/4885CYP1A2 939/4885PTGS1 1154/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | LMNA 3256/4885CYP1A2 4354/4885PTGS1 1593/4885 |
| US-11084842-B2 | Glucopyranosyl derivative and use thereof | SLC5A1, SLC5A2, UGGT1 | LMNA 4427/4885CYP1A2 939/4885PTGS1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.